CWA-sTT reflects residual FVIII; thus, it may be useful in differentially diagnosing AiFVIIID from hemophilia A. Coagulation abnormalities in the presence of emicizumab cannot be assessed using APTT; however, they could be monitored using CWA-sTT. This evidence concerns the gene F8 and hemophilia A.